KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Deferred Taxes (2016 - 2025)

Vertex Pharmaceuticals has reported Deferred Taxes over the past 15 years, most recently at $30.5 million for Q4 2025.

  • Quarterly results put Deferred Taxes at $30.5 million for Q4 2025, down 40.89% from a year ago — trailing twelve months through Dec 2025 was -$510.8 million (down 46.44% YoY), and the annual figure for FY2025 was -$510.8 million, down 46.44%.
  • Deferred Taxes for Q4 2025 was $30.5 million at Vertex Pharmaceuticals, up from -$235.9 million in the prior quarter.
  • Over the last five years, Deferred Taxes for VRTX hit a ceiling of $148.1 million in Q4 2022 and a floor of -$237.9 million in Q2 2021.
  • Median Deferred Taxes over the past 5 years was -$117.2 million (2023), compared with a mean of -$91.3 million.
  • Biggest five-year swings in Deferred Taxes: soared 453.46% in 2022 and later crashed 821.95% in 2023.
  • Vertex Pharmaceuticals' Deferred Taxes stood at -$41.9 million in 2021, then soared by 453.46% to $148.1 million in 2022, then tumbled by 188.45% to -$131.0 million in 2023, then surged by 139.39% to $51.6 million in 2024, then plummeted by 40.89% to $30.5 million in 2025.
  • The last three reported values for Deferred Taxes were $30.5 million (Q4 2025), -$235.9 million (Q3 2025), and -$113.8 million (Q2 2025) per Business Quant data.